<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188733</url>
  </required_header>
  <id_info>
    <org_study_id>10-005739</org_study_id>
    <nct_id>NCT01188733</nct_id>
  </id_info>
  <brief_title>Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis</brief_title>
  <official_title>Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Octreotide is used to control variceal bleeding. However, octreotide has to be given through
      the vein and is effective for less than two hours.

      In this study the investigators determined whether a long-acting preparation of octreotide
      (Sandostatin LAR)given as an intra-muscular injection every month could decrease portal
      pressure, and thus be used to prevent variceal bleeding in patients with cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <completion_date type="Actual">December 2000</completion_date>
  <primary_completion_date type="Actual">July 2000</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <condition>Esophageal Varices</condition>
  <arm_group>
    <arm_group_label>Sandostatin LAR 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sandostatin LAR ( long-acting octreotide) administered every 28 days in a dose of 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sandostatin LAR 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comparison of drug doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long acting octreotide 10mg</intervention_name>
    <description>Comparison of different doses</description>
    <arm_group_label>Sandostatin LAR 10mg</arm_group_label>
    <other_name>Long-acting octreotide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long acting Octreotide 30mg</intervention_name>
    <description>Comparison of drug doses</description>
    <arm_group_label>Sandostatin LAR 30mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Comparison of drug doses</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cirrhosis documented by biopsy, or suggested by characteristic features on abdominal
             imaging (nodular appearance, irregular contour) along with impaired synthetic liver
             function and thrombocytopenia and Child Turcotte Pugh Class A or B.

          2. presence of small esophageal varices, defined as varices &lt; 5 mm in diameter, without
             red signs documented on endoscopy within 3 months of enrollment

          3. age â‰¥ 18 years

        Exclusion Criteria:

          -  pregnant, lactating or of child-bearing potential and not practicing acceptable method
             of birth control

          -  allergic to sandostatin

          -  high risk varices on endoscopy carried out within 3 months of assessment (large
             varices or red signs)

          -  Child Turcotte Pugh Class C cirrhosis

          -  hepatocellular carcinoma

          -  evidence of ongoing alcohol or illicit drug abuse within 6 months of the study

          -  serum creatinine greater than 2 mg/dL

          -  platelet count below 50,000 per microliter

          -  prothrombin time 4 seconds or more greater than control

          -  human immunodeficiency virus (HIV) positive

          -  symptomatic gallstones

          -  previous history of upper gastrointestinal bleeding in the past 3 months, defined as
             hematemesis and/or melena

          -  previous history of variceal bleeding

          -  history of congestive heart failure , unstable angina, sustained ventricular
             tachycardia, or ventricular fibrillation

          -  use of any investigational drug within 1 month prior to screening and

          -  current use of beta blockers or long-acting nitrates, any other drug therapy known to
             have an influence on portal pressure (diuretics were allowed provided patients were on
             a stable dose for at least 30 days).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2010</study_first_posted>
  <last_update_submitted>August 24, 2010</last_update_submitted>
  <last_update_submitted_qc>August 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Patrick S. Kamath</name_title>
    <organization>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester MN 55905</organization>
  </responsible_party>
  <keyword>portal hypertension</keyword>
  <keyword>varices</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>octreotide</keyword>
  <keyword>somatostatin analog</keyword>
  <keyword>Child Pugh Class A,B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

